|Videos|December 9, 2022

Dr. Jonasch on HIF-2α inhibitors in renal cell carcinoma

Eric Jonasch, MD, discusses the potential of HIF-2α inhibitors, an emerging class of agents for the treatment of patients with renal cell carcinoma. Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.